Alyeska Investment Group
COCP icon

Alyeska Investment Group’s Cocrystal Pharma COCP Stock Holding History

Alyeska Investment Group’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-229,175
Closed -$3.44M – 698
2021
Q2 		$3.44M Buy
+229,175
New +$3.48M 0.04% 416

Other funds holding COCP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Alyeska Investment Group's COCP Position: Q3 2021 in Review

Alyeska Investment Group sold out of Cocrystal Pharma (COCP) in Q3 2021, closing a stake of 229,175 shares — an estimated $3.44M sold.

Alyeska Investment Group first reported a position in COCP in Q2 2021 and held it in 1 quarter. The position peaked at $3.44M in Q2 2021. 41 funds tracked by Wall St. Rank hold COCP as of Q3 2021.

  • Alyeska Investment Group reported no remaining Cocrystal Pharma position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 229,175 Cocrystal Pharma shares in Q3 2021, an estimated $3.44M.
  • Alyeska Investment Group first reported a position in Cocrystal Pharma in Q2 2021 and held it in 1 quarter.
  • Alyeska Investment Group's Cocrystal Pharma position peaked at $3.44M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.